# Dose-finding, Safety, Efficacy Trial of Topical Resiquimod in Patients With Multiple Actinic Keratosis Lesions

> **NCT01583816** · PHASE2 · COMPLETED · sponsor: **Spirig Pharma Ltd.** · enrollment: 218 (actual)

## Conditions studied

- Actinic Keratosis

## Interventions

- **DRUG:** Resiquimod 0.03%
- **DRUG:** Resiquimod 0.01%
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT01583816
- **Lead sponsor:** Spirig Pharma Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-05
- **Primary completion:** 2013-11
- **Final completion:** 2014-06
- **Target enrollment:** 218 (ACTUAL)
- **Last updated:** 2015-12-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01583816

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01583816, "Dose-finding, Safety, Efficacy Trial of Topical Resiquimod in Patients With Multiple Actinic Keratosis Lesions". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT01583816. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*